Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.

Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ.

J Pathol. 2007 Sep;213(1):82-90.

PMID:
17607666
2.

An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.

Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, Derisi JL, Chow SA, Silverman RH.

Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60.

3.

Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis.

Lin Y, Liu G, Zhang Y, Hu YP, Yu K, Lin C, McKeehan K, Xuan JW, Ornitz DM, Shen MM, Greenberg N, McKeehan WL, Wang F.

Development. 2007 Feb;134(4):723-34.

4.

Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14477-82. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17554.

5.

Post-translational modifications of steroid receptors.

Faus H, Haendler B.

Biomed Pharmacother. 2006 Nov;60(9):520-8. Review.

PMID:
16949786
6.

Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.

Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7789-94.

7.

Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.

Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S.

J Cell Biochem. 2006 Aug 15;98(6):1408-23. Review.

PMID:
16619263
8.

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.

Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM.

J Biol Chem. 2006 Jun 9;281(23):15694-700.

9.

Fibroblasts in cancer.

Kalluri R, Zeisberg M.

Nat Rev Cancer. 2006 May;6(5):392-401. Review.

PMID:
16572188
10.

Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.

Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P.

Cancer Res. 2006 Feb 15;66(4):2188-94.

11.

Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.

Hill R, Song Y, Cardiff RD, Van Dyke T.

Cell. 2005 Dec 16;123(6):1001-11.

12.

Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment.

Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, Feng B, Balagurunathan Y, Trent JM, Nickoloff BJ, Seftor RE, Hendrix MJ.

Cancer Res. 2005 Nov 15;65(22):10164-9.

13.

Mechanisms underlying differential responses to FGF signaling.

Dailey L, Ambrosetti D, Mansukhani A, Basilico C.

Cytokine Growth Factor Rev. 2005 Apr;16(2):233-47. Review.

PMID:
15863038
14.

Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.

Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL.

Oncogene. 2005 Jul 28;24(32):5053-68.

15.

The role of fibroblast growth factors and their receptors in prostate cancer.

Kwabi-Addo B, Ozen M, Ittmann M.

Endocr Relat Cancer. 2004 Dec;11(4):709-24. Review.

16.
17.

Stromal fibroblasts in cancer initiation and progression.

Bhowmick NA, Neilson EG, Moses HL.

Nature. 2004 Nov 18;432(7015):332-7. Review.

18.

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17456-61.

19.

Detection and expression of human BK virus sequences in neoplastic prostate tissues.

Das D, Shah RB, Imperiale MJ.

Oncogene. 2004 Sep 16;23(42):7031-46.

PMID:
15258563
20.

Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD.

Cancer Res. 2004 Mar 15;64(6):2270-305. Review.

Items per page

Supplemental Content

Support Center